Investing.com – Biomarin Pharma (NASDAQ:) reported on Thursday first quarter that beat analysts’ forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $0.09 on revenue of $486M. Analysts polled by Investing.com anticipated EPS of $-0.0923 on revenue of $446.78M.
Biomarin Pharma shares are down 8.5% from the beginning of the year, still down 39.19% from its 52 week high of $131.95 set on July 21, 2020. They are under-performing the Nasdaq which is up 9.27% from the start of the year.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma’s report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B.
Abbott Labs had beat expectations on April 20 with first quarter EPS of $1.32 on revenue of $10.46B, compared to forecast for EPS of $1.27 on revenue of $10.69B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment